Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter 4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively Affirms expectations for 1Q22 continued growth and ful

Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter

diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively

expectations for 1Q22 continued growth and full-year 2022 profitability

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (February 10, 2022) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,

non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results

for the three and 12 months ended December 31, 2021.

from the fourth quarter of 2021 and recent weeks include the following (all comparisons are with the fourth quarter of 2020, unless otherwise

revenues for the fourth quarter were significantly higher than for any quarter in the company's history, and I congratulate the

Sensus team on outstanding Q4 and full-year financial results," said Joe Sardano, chairman and chief executive officer of Sensus

Healthcare. "We are comfortable that this momentum will continue through 2022 as so many of our initiatives are being very well-executed.

"We shipped a record 35 systems during the

fourth quarter, including three systems to China, where we resumed active sales this year following the pandemic. China is an important

market for us, and we were delighted to receive a license renewal from their Ministry of Health to market the SRT-100

system. This new license runs through December 2026 and covers the sale of our superficial radiation therapy to treat non-melanoma

skin cancer and keloids."

domestic sales were positively impacted by our team's broad and consistent communication that the Centers for Medicare and Medicaid

Services had revalued procedure codes upward, with a meaningful increase in reimbursement for a course of superficial radiation treatment

for non-melanoma skin cancer. This revaluation has had a significant impact on customer ROI. In addition, we successfully demonstrated

to physicians that SRT is a patient-friendly treatment paradigm, especially important during COVID-19, and provided numerous studies

along with support from important medical societies showing cure rates as good as or better than Mohs surgery."

Mr. Sardano added, "We are highly encouraged

by the reception our new fair-market-leasing program has enjoyed to date. Launched in January 2021 in conjunction with improved reimbursement,

this program allows physicians to acquire our feature-rich, premium SRT-100 Vision system

with a positive ROI from treating just two patients per month. We expect the leasing program will support further sales growth."

the fourth quarter we entered into an exclusive U.S. distribution agreement with Mattioli Eng. Italia for its TransDermal Infusion System

for non-invasive drug delivery. We began marketing this FDA-cleared system for skin rejuvenation treatments, pre-laser treatments, pre-

and post-plastic surgery, and other applications, and were delighted that it was highlighted at the Winter Clinical Dermatology Conference

in Hawaii. We are pleased with the number and caliber of leads generated at the conference, and look forward to demonstrating the system

at the American Academy of Dermatology meeting in Boston at the end of March.

Sardano concluded, "We are confident that our sales and earnings trajectory will continue, and with a view toward long-term success

we recently announced key executive appointments. We promoted two sales managers to regional vice president positions and promoted Vice

President & General Counsel Michael J. Sardano to President & General Counsel. These promotions, along with the market reception

to our products, support my optimism for the future of Sensus."

Quarter Financial Results

for the fourth quarter of 2021 were $13.0 million, compared with $5.1 million for the fourth quarter of 2020. The 156% increase was primarily

driven by a higher number of units sold as the market continued to reopen.

of sales for the fourth quarter of 2021 was $4.2 million, compared with $1.9 million for the prior-year quarter. The increase was due

to higher sales in the 2021 period.

profit for the fourth quarter of 2021 was $8.9 million, or 68.0% of revenues, compared with $3.2 million, or 63.4% of revenues, for the

fourth quarter of 2020. The increases were primarily driven by the higher number of units sold in 2021, service revenue on installed

units, and the impact of COVID-19 on the 2020 quarter.

and marketing expense for the fourth quarter of 2021 was $1.3 million, unchanged from the fourth quarter of 2020.

and administrative expense for the fourth quarter of 2021 was $1.1 million, compared with $0.8 million for the fourth quarter of 2020.

The increase was primarily due to higher compensation and bad debt expense.

and development expense for the fourth quarter of 2021 was $1.1 million, compared with $0.8 million for the prior-year quarter. The increase

was mainly due to higher regulatory expenses.

income for the fourth quarter of 2021 was $5.3 million, or $0.32 per diluted share, compared with net income of $1.0 million, or $0.06

per diluted share, for the fourth quarter of 2020.

EBITDA for the fourth quarter of 2021 was $5.6 million, compared with $1.3 million for the fourth quarter of 2020. Adjusted EBITDA, a

non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense.

Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial

measures are provided.

and investments were $14.5 million as of December 31, 2021, compared with $14.9 million as of December 31, 2020. The company had no outstanding

borrowings under its revolving line of credit both during 2020 and as of December 31, 2021.

Year Financial Results

for 2021 of $27.0 million increased 182% from $9.6 million for 2020, primarily reflecting a higher number of units sold as the market

began to reopen. During 2020 the Company was unable to sell effectively due to COVID-19 related travel restrictions and other factors.

Sensus believes these factors are gradually subsiding as the healthcare industry has developed and continues to develop effective vaccines

and treatments, and as local, state and federal governments ease restrictions. Additionally, technology that enables the global business

community to communicate effectively without the need for close proximity is expected to help the Company continue to reach potential

of sales for 2021 were $10.1 million, compared with $4.3 million for 2020, reflecting the higher number of units sold.

profit for 2021 increased 224% to $17.0 million, or 68.2% of revenues, from $5.2 million, or 54.8% of revenues, for 2020. Maintaining

this level of gross profit and gross margin in 2022 is largely dependent upon the market's response to the ongoing COVID-19 pandemic.

and marketing expense for 2021 was $4.8 million, compared with $5.3 million in 2020, primarily attributable reduced spending on marketing

activities and headcount.

and administrative expense for 2021 was $4.6 million, compared with $4.0 million in 2020, due primarily to higher insurance expense and

and development expense for 2021 decreased to $3.4 million from $4.2 million in 2020, reflecting lower spending as the Sculptura

project entered the production phase.

other income was reported for 2021. Other income, net of $1.4 million for 2020 is primarily attributable to the forgiveness of $757,782

of a loan under the Small Business Administration Paycheck Protection Program and a bargain purchase gain of $588,011 that was recorded

as a result of acquisitions.

income for 2021 was $4.1 million, or $0.25 per diluted share, compared with a net loss of $(6.8) million, or $(0.42) per share, for 2020.

EBITDA for 2021 was $5.1 million, compared with $(5.8) million for 2020.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally

accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis

of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute

for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the

impact of interest, income taxes, depreciation, amortization and stock compensation expense, provides useful supplemental information

that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally

defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to

GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts

who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation

of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time, during which management will

discuss financial results for the 2021 fourth quarter and full year, provide a business update and answer questions. To access the conference

call the dial-in numbers are 888-390-3967 (U.S. and Canada) or 862-298-0702 (International). Please direct the operator to be connected

to the Sensus Healthcare conference call. The call will be webcast live and can be accessed at the following link, which also may be

found in the Investor Relations section of the Company's website at www.sensushealthcare.com.

the conclusion of the conference call, a replay will be available and can be accessed by dialing 888-539-4649 (U.S. and Canada) or 754-333-7735

(International). At the system prompt, dial the replay code 156817 followed by the # sign. Playback will automatically begin. An archived

webcast of the call will also be available in the Investor Relations section of the Company's website for a period of time.

Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments

for both oncological and non-oncological conditions. The Sculptura modulated robotic brachytherapy radiation oncology system provides

targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting

to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary

low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research